

ABIOMED INC
Form 4
May 17, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Weber David M

(Last) (First) (Middle)

C/O ABIOMED, INC., 22 CHERRY
HILL DRIVE

(Street)

DANVERS, MA 01923

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
ABIOMED INC [ABMD]

3. Date of Earliest Transaction
(Month/Day/Year)

05/15/2017

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title below) ____ Other (specify
below)

Chief Operating Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$.01 par value	05/15/2017		F ⁽⁵⁾	5,301 ⁽⁵⁾	D \$ 131.42	97,220	D
Common Stock, \$.01 par value	05/15/2017		A ⁽⁶⁾	10,434 ⁽⁶⁾	A \$ 0	107,654	D
Common Stock, \$.01 par value	05/15/2017		A ⁽⁷⁾	3,000 ⁽⁷⁾	A \$ 0	110,654	D

Edgar Filing: ABIOMED INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) ⁽²⁾	\$ 10.03							06/03/2011 ⁽¹⁾	06/03/2020	Common Stock	0
Stock Option (right to buy) ⁽²⁾	\$ 22.44							05/22/2013 ⁽¹⁾	05/22/2022	Common Stock	0
Stock Option (Right to Buy) ⁽²⁾	\$ 23.15							05/14/2014 ⁽¹⁾	05/14/2023	Common Stock	0
Stock Option (Right to Buy) ⁽²⁾	\$ 21.55							05/14/2015 ⁽³⁾	05/14/2024	Common Stock	0
Stock Option (right to buy) ⁽²⁾	\$ 66.25							05/13/2016 ⁽³⁾	05/13/2025	Common Stock	0
Stock Option (right to buy) ⁽⁴⁾	\$ 99.62							05/24/2017 ⁽³⁾	05/24/2026	Common Stock	0
Stock Option	\$ 134.51	05/15/2017		A		8,000		05/15/2018 ⁽³⁾	05/15/2027	Common Stock	8,000

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Weber David M C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923			Chief Operating Officer	

/s/ Stephen C. McEvoy (by power of attorney) 05/17/2017

- | | |
|-----|--|
| * | If the form is filed by more than one reporting person, <i>see</i> Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. <i>See</i> 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | This option becomes exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. |
| (2) | Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. |
| (3) | These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. |
| (4) | Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. |
| (5) | Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. |
| (6) | Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. |
| (7) | Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates. |